DEAR EDITOR, Ustekinumab is a human monoclonal antibody directed against the p40
subunit of both interleukin (IL)-12 and IL-23. 1 It has been shown to be very effective in …

DEAR EDITOR, Psoriasis is an inflammatory skin disease that affects approximately 2–3% of
the population. 1 Patients with psoriasis are at risk of developing psoriatic arthritis (PsA), an …

DEAR EDITOR, Despite the availability of highly efficacious biologics, psoriasis still remains
an area of medical need. 1, 2 In particular, manifestations of the disease in different organs …

DEAR EDITOR, Currently available biologics for psoriasis target the function of tumour
necrosis factor (TNF)-a, interleukin (IL)-17A or IL-12/23, and include etanercept (anti-TNF …

DEAR EDITOR, With the widespread use of monoclonal antibodies directed against
cytokines in the treatment of psoriasis, we are presented with opportunities to investigate …

DEAR EDITOR, Several therapeutic antibodies are available for the treatment of chronic
plaque-type psoriasis. Ustekinumab (a monoclonal interleukin-12/23 antagonist) is one of …

DEAR EDITOR, Exacerbation/reactivation of chronic hepatitis B virus (HBV) and hepatitis C
virus (HCV) in people with psoriasis during treatment with biologics is a concern with the use …

MADAM, The reactivation of the hepatitis B virus (HBV) during immunosuppressive therapy
has already been reported, even in hepatitis B surface antigen (HBsAg)-negative patients …

DEAR EDITOR, Ustekinumab is increasingly used for treatment of autoimmune diseases. To
date, clinical trial data suggest its safety. Here we report a case of severe, disseminated …

DEAR EDITOR, Ustekinumab is a human monoclonal antibody, which binds to and inhibits
interleukin (IL)-12p40, and is used to treat moderate-to-severe psoriasis and psoriatic …